Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma
Phase 2
Completed
- Conditions
- Melanosis
- Interventions
- Drug: Trio KligmanDrug: New trio de Kligman
- Registration Number
- NCT05119413
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Brief Summary
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed
Exclusion Criteria
- Pregnant woman
- Other pigmentary disorder affecting the face
- Use of systemic or topical steroids or retinoids, use of topical depigmenting agents or depigmenting procedure in the month before the inclusion
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Kligman's trio Trio Kligman Application once a day for 12 weeks New traitement New trio de Kligman Thiamidol, retinoid, topical steroid preparation
- Primary Outcome Measures
Name Time Method The melasma's type at 12 weeks Clinical score MASI
- Secondary Outcome Measures
Name Time Method the Quality of life of patient at 12 weeks descriptive name of scale : meslascol
Trial Locations
- Locations (1)
CHU de Nice
🇫🇷Nice, Alpes-maritimes, France